Cindy Eckert first learned about hypoactive sexual desire disorder (HSDD)—the most common type of sexual dysfunction in women—while attending a conference as a cofounder of Slate Pharmaceuticals, a ...
The MarketWatch News Department was not involved in the creation of this content. Recognition follows Addyi's newly expanded FDA approval to treat both premenopausal and postmenopausal women under age ...
S1 Biopharma is a developer of first-in-class drugs for sexual dysfunction in both women and men. The company's lead compound, Lorexys, is currently in Phase IIb for the treatment of hypoactive sexual ...
Credit: Sprout Pharmaceuticals The approval was based on a randomized, double-blind, placebo-controlled phase 3 trial, which included 447 postmenopausal women with acquired, generalized HSDD.
(StatePoint) Forty-two percent of women experience sexual dysfunction -- and Hypoactive Sexual Desire Disorder (HSDD) -- characterized as frustrating low libido, is the most common form of it. It is ...
About one in five women who reach menopause lists a loss of libido, or sex drive, as a symptom, along with difficulties with ...
RALEIGH, N.C., Jan. 29, 2026 /PRNewswire/ -- Sprout Pharmaceuticals today announced that Addyi® has been named "Best Prescription for Low Libido" in the 2026 Oprah Daily Menopause O-wards, one of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results